|
|
|
18.03.26 - 21:06
|
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board (GlobeNewswire EN)
|
|
|
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
24.12.25 - 19:09
|
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® (GlobeNewswire EN)
|
|
|
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50% and expanding its First Defense® manufacturing capabilities....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
